Biotech Values

[walldiver]

The clinical investigator Dr. Celestia Higano on 9902A submitted an abstract in December in order to make the deadline. She probably didn't know at the time that DNDN was planning on unblinding 9902A for the progression data. When DNDN announced the progression miss and the interim 9902A survival data in January, they asked ASCO to pull the presentation. ASCO did, but apparently failed to inform their webmaster. Within one day or so of seeing it show up on the website, it was pulled from the website. Apparently, after January, it never was on the official agenda.

Both Dr. Higano and DNDN have confirmed this, just not with a press release.